Vasoactive intestinal peptide, periodontal disease, and the innate immune response: an interview with Dr. John J. Taylor. Interview by Helene F. Rosenberg.
Taylor
John J
JJ
D007113:Immunity, Innate; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors; D009000:Monocytes / Q000378:metabolism / Q000502:physiology*; D010510:Periodontal Diseases / Q000276:immunology* / Q000382:microbiology; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051195:Toll-Like Receptor 2 / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000378:metabolism; D015534:Trans-Activators / Q000378:metabolism; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*; D000099232:Proto-Oncogene Protein Spi-1
D008070:Lipopolysaccharides; D011518:Proto-Oncogene Proteins; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D015534:Trans-Activators; D014660:Vasoactive Intestinal Peptide; D000099232:Proto-Oncogene Protein Spi-1; C495342:TLR2 protein, human; C495345:TLR4 protein, human